Reviews:
Molecular characterization of circulating tumor cells in lung cancer: moving beyond enumeration
PDF | HTML | How to cite
Metrics: PDF 1451 views | HTML 2036 views | ?
Abstract
Lei Wang1,2, Coraline Dumenil3, Catherine Julié4,5, Violaine Giraud3, Jennifer Dumoulin3, Sylvie Labrune3, Thierry Chinet3,5, Jean-François Emile4,5, Biao He2 and Etienne Giroux Leprieur3,5
1Department of Thoracic Surgery, Fourth Hospital of Hebei Medical University, Shijiazhuang, Hebei, China
2Thoracic Oncology Program, Department of Surgery, Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, CA, USA
3Department of Respiratory Diseases and Thoracic Oncology, APHP – Ambroise Pare Hospital, Boulogne-Billancourt, France
4Department of Pathology, APHP – Ambroise Pare Hospital, Boulogne-Billancourt, France
5EA 4340 “Biomarqueurs en Cancérologie et Onco-Hématologie” UVSQ, Paris-Saclay University, Boulogne-Billancourt, France
Correspondence to:
Etienne Giroux Leprieur, email: [email protected]
Keywords: lung cancer; circulating tumor cells; prognosis; predictive marker; molecular diagnosis
Received: August 05, 2017 Accepted: September 20, 2017 Published: November 23, 2017
ABSTRACT
Molecular characterization of tumor cells is a key step in the diagnosis and optimal treatment of lung cancer. However, analysis of tumor samples, often corresponding to small biopsies, can be difficult and does not accurately reflect tumor heterogeneity. Recent studies have shown that isolation of circulating tumor cells (CTCs) is feasible in non-small cell lung cancer patients, even at early disease stages. The amount of CTCs corresponds to the metastatic potential of the tumor and to patient prognosis. Moreover, molecular analyses, even at the single-cell level, can be performed on CTCs. This review describes the technologies currently available for detecting and capturing CTCs, the potential for downstream molecular diagnostics, and the clinical applications of CTCs isolated from lung cancer patients as screening, prognostic, and predictive tools. Main limitations of CTCs are also discussed.
All site content, except where otherwise noted, is licensed under a Creative Commons Attribution 4.0 License.
PII: 22651